Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of GSK malaria vaccine SB257049 schedules in children 5-17 months old
PACTR201905692900706Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- Sep 2017
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, randomised trial of RTS,S/AS02A and Rabies vaccine in malaria (5 arms), sponsored by GSK. Primary endpoint: Occurrence of clinical malaria meeting the primary case definition. Planned start Sep 2017; status: not yet recruiting.
02
Drugs
RTS,S/AS02ARabies vaccine
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR201905692900706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201905692900706.